Onset of clinical effects and plasma concentration of fluvoxamine in japanese patients

Biological and Pharmaceutical Bulletin

Volumn 33, Issue 12, 2010, Pages 1999-2002

  Katoh, Yasuhiro ^a   Uchida, Shinya ^a   Kawai, Masayoshi ^b   Takei, Noriyoshi ^b   Mori, Norio ^b   Kawakami, Junichi ^b   Kagawa, Yoshiyuki ^a   Yamada, Shizuo ^a   Namika, Noriyuki ^a   Hashimoto, Hisakuni ^c  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NIHON PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Antidepressant response; Fluvoxamine; Hamilton rating scale for depression; Plasma concentration

Indexed keywords

FLUVOXAMINE MALEATE;

ADULT; ARTICLE; BEHAVIOR CHANGE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MONITORING; DRUG RESPONSE; EVENING DOSAGE; FEMALE; HAMILTON SCALE; HUMAN; JAPANESE; MALE; MENTAL HEALTH; MORNING DOSAGE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREDICTION; TREATMENT DURATION;

ADULT; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; DEPRESSIVE DISORDER; EATING DISORDERS; FEMALE; FLUVOXAMINE; HUMANS; JAPAN; MALE; MIDDLE AGED; MOOD DISORDERS; ROC CURVE; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 78751480817     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.33.1999     Document Type: Article

References (23)

1. Kessler R. C., McGonagle K. A., Zhao S., Nelson C. B., Hughes M., Eshleman S., Wittchen H. U., Kendler K. S., Arch. Gen. Psychiatry, 51, 8-19 (1994).
2. Robins L. N., Regier D. A., "Psychiatric Disorders in America, The Epidemiologic Catchment Area Study," The Free Press, New York, 1991.
3. Kessler R. C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K. R., Rush A. J., Walters E. E., Wang P. S., JAMA, 289, 3095-3105 (2003).
4. Boland R. J., Keller M. B., "Psychiatry Therapeutics," 2nd ed., ed. by Tasman A., Kay J., Lieberman L. A., Hoboken, Wiley, NJ, 2003, pp. 292-334.
5. Cates M., Am. J. Pharm. Educ., 65, 190-194 (2001).
6. National Collaborating Centre for Mental Health, "Depression: Management of Depression in Primary and Secondary Care," National Institute for Clinical Excellence, London, England, 2004 (Clinical Guideline 23).
7. Stahl S. M., Nierenberg A. A, Gorman J. M., J. Clin. Psychiatry, 62, (Suppl.), 17-23, discussion 37-40 (2001).
8. Wilde M. I., Plosker G. L., Benfield P., Drugs, 46, 895-924 (1993).
9. Berlin I., Lavergne F., Eur. Psychiatry, 13, 138-142 (1998).
10. Dominguez R. A., Goldstein B. J., Jacobson A. F., Steinbook R. M., J. Clin. Psychiatry, 46, 84-87 (1985).
11. Claghorn J. L., Earl C. Q., Walczak D. D., Stoner K. A., Wong L. F., Kanter D., Houser V. P., J. Clin. Psychopharmacol., 16, 113-120 (1996).
12. Taylor M. J., Freemantle N., Geddes J. R., Bhagwagar Z., Arch. Gen. Psychiatry, 63, 1217-1223 (2006).
13. Itil T. M., Shrivastava R. K., Mukherjee S., Coleman B. S., Michael S. T., Br. J. Clin. Pharmacol., 15 (Suppl.), 433S-438S (1983).
14. Roth D., Mattes J., Sheehan K. H., Sheehan D. V., Prog. Neuropsychopharmacol. Biol. Psychiatry, 14, 929-939 (1990).
15. Linder M. W., Keck P. E., Clin. Chem., 44, 1073-1084 (1998).
16. Kasper S., Dötsch M., Kick H., Vieira A., Möller H. J., Eur. Neuropsychopharmacol., 3, 13-21 (1993).
17. DeVane C. L., Gill H. S., J. Clin. Psychiatry, 58 (Suppl.), 7-14 (1997).
18. American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorder," 4th, Washington D.C., 1994.
19. Hamilton. M., British Journal of Social and Clinical Psychology, 6, 278-296 (1967).
20. American Psychiatric Association, Am. J. Psychiatry, 157, 1-45 (2000).
21. Katoh Y., Uchida S., Kawai M., Takei N., Mori N, Kawakami J., Kagawa Y., Yamada S., Namiki N., Hashimoto H., Biol. Pharm. Bull., 33, 285-288 (2010).
22. Perry P. J., Zeilmann C., Arndt S., J. Clin. Psychopharmacol., 14, 230-240 (1994).
23. Härtter S., Wetzel H., Hammes E., Torkzadeh M., Hiemke C., Pharmacopsychiatry, 31, 199-200 (1998).